FGFR2 is a Candidate Immune‐Associated Marker of Diabetic Foot Ulcer That Promotes Keratinocyte Function by Activating the PI3K/Akt and MAPK Pathways | Synapse
April 17, 2026Open Access
FGFR2 is a Candidate Immune‐Associated Marker of Diabetic Foot Ulcer That Promotes Keratinocyte Function by Activating the PI3K/Akt and MAPK Pathways
Puntos clave
The aim is to investigate the role of FGFR2 in diabetic foot ulcers and its potential as a biomarker and treatment target.
Assessment of FGFR2 expression levels in diabetic foot ulcer samples.
Analysis of the activation of PI3K/Akt and MAPK pathways.
Evaluation of keratinocyte functions related to FGFR2 activation.
FGFR2 is found to be lowly expressed in diabetic foot ulcers.
Activation of the PI3K/Akt pathway by FGFR2 enhances keratinocyte function.
FGFR2 is identified as a potential diagnostic marker and therapeutic target for diabetic foot ulcers.
Resumen
FGFR2 is lowly expressed in DFU and can exert a protective effect by activating the PI3K/Akt pathway. It is a candidate diagnostic biomarker and potential therapeutic target for DFU.